Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Edwards Lifesciences Corporation
  6. Summary
    EW   US28176E1082

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  05/20 04:00:02 pm EDT
94.32 USD   -0.05%
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Buy Rating
MT
05/16Edwards announces key events for europcr 2022
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
95.93(c) 97.39(c) 93.41(c) 94.37(c) 94.32 Last
2 385 156 2 269 599 2 155 679 2 407 047 2 956 632 Volume
-1.66% +1.52% -4.09% +1.03% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 5 734 M - -
Net income 2022 1 558 M - -
Net cash position 2022 1 316 M - -
P/E ratio 2022 38,2x
Yield 2022 -
Sales 2023 6 412 M - -
Net income 2023 1 724 M - -
Net cash position 2023 2 470 M - -
P/E ratio 2023 34,6x
Yield 2023 -
Capitalization 58 675 M 58 675 M -
EV / Sales 2022 10,0x
EV / Sales 2023 8,77x
Nbr of Employees 15 700
Free-Float 96,5%
More Financials
Company
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - hemodynamic monitoring systems (67%); - heart valves and surgery products (17%); - other (16%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United... 
Read more
More about the company
Ratings of Edwards Lifesciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EDWARDS LIFESCIENCES CORPORATION
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/17Citigroup Adjusts Price Target on Edwards Lifesciences to $115 From $134, Reiterates Bu..
MT
05/16Edwards announces key events for europcr 2022
PR
05/11INSIDER SELL : Edwards Lifesciences
MT
05/04EDWARDS LIFESCIENCES CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
04/29INSIDER SELL : Edwards Lifesciences
MT
04/28EDWARDS LIFESCIENCES CORP Management's Discussion and Analysis of Financial Condition ..
AQ
04/28TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 5, 2021.
CI
04/28TRANCHE UPDATE ON EDWARDS LIFESCIENC : EW)'s Equity Buyback Plan announced on May 8, 2019.
CI
04/27Canaccord Genuity Adjusts Edwards Lifesciences' Price Target to $137 from $152, Keeps B..
MT
04/27Raymond James Adjusts Edwards Lifesciences' Price Target to $124 from $126, Keeps Outpe..
MT
04/27Goldman Sachs Adjusts Price Target for Edwards Lifesciences to $105 From $102, Maintain..
MT
04/27RBC Cuts Price Target on Edwards Lifesciences to $135 From $142, Maintains Outperform R..
MT
04/27SVB Leerink Adjusts Price Target on Edwards Lifesciences to $138 From $145, Keeps Outpe..
MT
04/26EDWARDS LIFESCIENCES : REPORTS FIRST QUARTER RESULTS - Form 8-K
PU
More news
News in other languages on EDWARDS LIFESCIENCES CORPORATION
05/11VENTE PAR DES INITIÉS : Edwards Lifesciences
04/29VENTE PAR DES INITIÉS : Edwards Lifesciences
04/26Le bénéfice du premier trimestre d'Edwards Lifesciences augmente grâce à la hausse des ..
04/26Edwards Lifesciences Corporation annonce ses résultats pour le premier trimestre clos l..
04/26Earnings Flash (EW) EDWARDS LIFESCIENCES CORPORATION affiche un revenu de 1,34 milliard..
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 94,37 $
Average target price 125,90 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-27.16%58 675
THERMO FISHER SCIENTIFIC-18.74%215 594
DANAHER CORPORATION-24.22%178 480
INTUITIVE SURGICAL, INC.-39.29%78 303
SIEMENS HEALTHINEERS AG-17.17%64 740
BOSTON SCIENTIFIC CORPORATION-7.04%56 454